Cordis Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the S.M.A.R.T.® CONTROL® Vascular Stent Systems for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery (PPA). The S.M.A.R.T.® Stent, which has been approved for peripheral indication in international markets since 1999, is now the first stent in the Unites States with both Iliac and SFA indications.
Boston Scientific Corporation (Natick, MA) announced the beginning of the MAJESTIC clinical trial of the company’s Innova peripheral vascular drug-eluting stent (DES) system.
Jan Brunkwall, from the Department of Vascular Surgery, University Clinics, University of Cologne, Germany, presented one-year results of ADSORB (A prospective randomised trial in acute uncomplicated type B dissections), the first ever randomised trial on acute uncomplicated type B dissections. Brunkwall presented the results at the European Society of Vascular Surgery annual meeting (ESVS, Bologna, Italy, 19–21 September) and at the Thoracic Aortic Masterclass, in September in London, UK.
Two studies presented at the Transcatheter Cardiovascular Therapeutics congress (TCT, Miami, USA, 22–26 October) showed that revascularisation with a drug-eluting balloon is a promising technique for the treatment of in-stent restenosis in the superficial femoral artery.
A study found that a nitinol stent performed better than balloon angioplasty alone in treating blockages of the popliteal artery, which runs through the leg behind the knee. Results of the ETAP trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
Results from the ETAP trial, presented by Thomas Zeller, professor of Clinic Cardiology and Angiology and chief of the Department of Angiology at Universitäts-Herzzentrum Freiburg Bad Krozingen, Germany, at the TCT congress, have found that a nitinol stent performed better than balloon angioplasty alone in treating blockages in the popliteal artery.
Among nearly 45,000 men who were followed up for more than two decades, those with the risk factors of smoking, hypertension, high cholesterol, and type 2 diabetes had an associated greater risk of developing peripheral arterial disease (PAD), according to a study published in the 24–31 October issue of the Journal of the American Medical Association (JAMA).
It looks as though drug-eluting balloons (DEBs) already widely used in Europe are set to burst into the global market, as heart conditions become a more common problem, states a new report by healthcare experts GBI Research.
Minimally invasive elective repairs of abdominal aortic aneurysms, potential deadly bulges in arteries, reduces vessel rupture and short-term, AAA-related mortality, according to a Beth Israel Deaconess Medical Center study.
New results from the PARTNER Cohort B trial presented at the TCT congress have shown that transcatheter aortic valve implantation (TAVI) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery.
October 24, 2012—The Cardiovascular Research Foundation (CRF) announced that results from the ETAP (Endovascular Treatment of Popliteal Artery–Balloon Angioplasty Versus Primary Stenting) trial were presented by lead investigator Thomas Zeller, MD, at the CRF’s TCT 2012: Transcatheter Cardiovascular Therapeutics conference in Miami, Florida. ETAP evaluated a nitinol stent versus balloon angioplasty alone in treating blockages of the popliteal artery.
Daniel Clair, chairman, Department of Vascular Surgery, The Cleveland Clinic Foundation, presented at the TCT congress twelve-month clinical endpoint data from the ORION trial, which demonstrated robust safety and effectiveness outcomes for the Epic Self-Expanding Nitinol Stent System (Boston Scientific) in patients with iliac artery disease.
A computerised checklist system designed to help physicians identify and use the best methods of preventing potentially venous thromboembolism (VTE) in hospitalised trauma patients dramatically reduced the number of these dangerous VTEs, according to researchers from the Johns Hopkins University School of Medicine, Baltimore, USA.
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of the oral anticoagulant rivaroxaban for the treatment of pulmonary embolism and prevention of recurrent pulmonary embolism and deep vein thrombosis.
October 23, 2012—In the Journal of the American College of Cardiology: Cardiovascular Interventions, George Dangas, MD, et al published findings of a meta-analysis of randomized trials comparing open versus endovascular stent graft repair of abdominal aortic aneurysms (AAA) (2012;5:1071–1080). The study sought to evaluate short-, intermediate-, and longer-term outcomes, including both AAA-related and all-cause mortality.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos